HCB101: a novel potent ligand-trap Fc-fusion protein targeting the CD47-SIRPα pathway with high safety and preclinical efficacy for hematological and solid tumors
HCB101:一种新型强效配体陷阱Fc融合蛋白,靶向CD47-SIRPα通路,具有高安全性和临床前疗效,可用于治疗血液肿瘤和实体瘤。
期刊:Journal of Hematology & Oncology
影响因子:40.4
doi:10.1186/s13045-025-01742-x
Wang, Jiin-Tarng; Tseng, Chi-Ling; Teng, Han-Fang; Kuo, Pan-Hsien; Cheng, Yun-Chih; Chen, Yi-Jing; Lu, Yi-Hsuan; Wang, Chun-Chung; Shen, Tsai-Kuei; Wang, Hong-Fan; Tsai, Pei-Lun; Wu, Yu-Chen; Ho, Chien-Hsin; Sun, Wei-Tse; Li, Yen-Cheng; Lee, Yi-Hsuan; Hung, Yu-Jiun; Chen, Mingyi; Li, Zihai; Juo, Zong Sean; Zhai, Wenwu; Liu, Scott Shi-Kau